BREEZE-AD5 Study Results: Efficacy and Safety of Baricitinib in Patients With Moderate to Severe Atopic Dermatitis

From the 2020 Annual Meetings of the American Academy of Allergy, Asthma, and Immunology (AAAAI), the American Academy of Dermatology (AAD), and Revolutionizing Atopic Dermatitis (RAD).
Significantly improved skin inflammation, pain, itch, sleep, and quality-of-life outcomes in patients with moderate to severe AD treated with baricitinib vs placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 160 KB
Released: August 11, 2020

Acknowledgements

Provided by Clinical Care Options.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This educational activity is supported by educational grants from
AbbVie Inc.
Pfizer Inc.

Related Content

A review on how new and emerging data in the management of atopic dermatitis will affect clinical practice: atopic dermatitis conference coverage from CCO

Andrew F. Alexis, MD, MPH Jonathan Silverberg, MD Released: September 21, 2020

Expert-authored commentary on investigational selective JAK inhibitors in atopic dermatitis treatment from Clinical Care Options (CCO)

Jonathan Silverberg, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 12, 2020 Expired: August 11, 2021

Expert-authored commentary on new data in atopic dermatitis treatment from the 2020 AAD and RAD conferences from Clinical Care Options (CCO)

Andrew F. Alexis, MD, MPH Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Released: August 10, 2020 Expired: August 9, 2021

Effect of withdrawal and retreatment with upadacitinib during an interim analysis of the 88-week phase 2b trial, from CCO

Released: July 27, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue